|
WO2021028559A1
|
|
Method for obtaining efficient compositions comprising viral vectors for vaccination or gene therapy
|
|
KR20190053908A
|
|
New method for stabilization of biopharmaceuticals during processing
|
|
WO2018050873A1
|
|
A novel method for producing low viscous and highly concentrated biopharmaceutical drug products in liquid formulation
|
|
US2019256551A1
|
|
A novel method of producing a liquid biopharmaceutical drug product
|
|
EP3512939A1
|
|
A novel method for obtaining efficient viral vector-based compositions for vaccination or gene therapy
|
|
WO2015059284A1
|
|
A novel method for the production of stabile vaccines
|
|
EP2913671A1
|
|
Novel coated carriers for the specific binding of target molecules
|
|
CN103620025A
|
|
Novel stabilisation method for viruses or bacteria
|
|
CN103649105A
|
|
Method for preventing the unfolding of a (poly) peptide and/or inducing the (re- ) folding of a (poly) peptide
|
|
EP2264453A1
|
|
Method for filtering blood
|
|
EP2236520A1
|
|
Stabilizing composition for immobilized biomolecules
|
|
EP2236617A1
|
|
Methods of terminal sterilization of biofunctional compositions
|
|
EP2058335A1
|
|
Biocompatible three dimensional matrix for the immobilization of biological substances
|
|
EP2055384A1
|
|
Device for identifying constituents in a fluid
|
|
US2009298078A1
|
|
Method for the detection of an activation of the immune system or the extent of cell death
|
|
JP2008119089A
|
|
Leukocyte stimulus matrix
|
|
EP1852443A1
|
|
Biocompatible three dimensional matrix for the immobilization of biological substances
|
|
EP1571204A1
|
|
Leukocyte stimulation matrix
|
